Tablets & Capsules


Issue link:

Contents of this Issue


Page 14 of 55

Tablets & Capsules March 2018 13 A continuing debate for established, emerging, and virtual biopharmaceutical companies is whether or not to outsource production to a CMO. At its core, the issue is about brand protection. While outsourcing can minimize your capital and labor costs, it can be challenging to evaluate CMOs and determine which one will best serve your needs as a manufacturing partner. Many factors influence the selection of a pharmaceutical contract manufacturing organization (CMO) beyond the price on the bid. This article discusses what to consider when choosing a CMO to manufacture your drug product. Choosing a contract manufacturing organization Christa Myers and Kevin Debbs CRB USA outsourcing

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - TC0318